Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · IEX Real-Time Price · USD
1.600
-0.010 (-0.62%)
At close: Apr 24, 2024, 4:00 PM
1.620
+0.020 (1.25%)
After-hours: Apr 24, 2024, 5:45 PM EDT
Company Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.
Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc.
| Country | United States |
| Founded | 1995 |
| IPO Date | Apr 7, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 285 |
| CEO | Lonnel Coats |
Contact Details
Address: 2445 Technology Forest Blvd., Suite 1100 The Woodlands, Texas 77381 United States | |
| Phone | (281) 863-3000 |
| Website | lexpharma.com |
Stock Details
| Ticker Symbol | LXRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001062822 |
| CUSIP Number | 528872302 |
| ISIN Number | US5288723027 |
| Employer ID | 76-0474169 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lonnel Coats | Chief Executive Officer and Director |
| Jeffrey L. Wade J.D. | President and Chief Financial Officer |
| Brian T. Crum | Senior Vice President, General Counsel and Secretary |
| Dr. Alan J. Main Ph.D. | Executive Vice President of Innovation and Chemical Sciences |
| Dr. Craig B. Granowitz M.D., Ph.D. | Senior Vice President and Chief Medical Officer |
| Kristen L. Alexander | Vice President of Finance and Accounting |
| Lisa M. DeFrancesco | Head of Investor Relations and Corporate Strategy |
| Dixon Terry | Vice President of Compliance |
| Carrie Siragusa | Vice President of Marketing |
| Desiree Gendron | Vice President of Sales and Training |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2024 | ARS | Filing |
| Mar 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 26, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 25, 2024 | 10-K | Annual Report |
| Mar 13, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 12, 2024 | 8-K | Current Report |
| Mar 11, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 11, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |